Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatological Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynaecological Cancers
Haematological Malignancies
Haematology
Head and Neck Cancer
Immunotherapy
Leukaemia
Lung Cancer
Lymphoma
Multiple Myeloma
Endocrine Cancers
Ovarian Cancer
Pancreatic Cancer
Paediatric Oncology
Policy
Prostate Cancer
Renal Cancer
Sarcoma
Supportive Cancer Care
Soft Tissue Tumours
Neuro-oncology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic

3D Rendered Medical Illustration of The Lungs.
12 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Mesothelioma and Immunotherapies

Asrar A Alahmadi, Logan Roof, Claire Verschraegen

Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to consider, with non-epithelioid subtypes responding better to immunotherapy than to chemotherapy (see the section on […]

touchREVIEWS in Oncology & Haematology. 2024;20(2):Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin

CME Accredited Learning

Our accredited content is designed to impact patient health outcomes, by ensuring that it provides you with a learning experience that will positively impact your clinical practice, based on adult learning preferences and intuitive instructional design. All activities are developed in collaboration with leading faculty and education partners.

touchONCOLOGY

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
90 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchSYMPOSIUM

Collaboration in chronic ITP: Improving quality of life and patient outcomes

Prof. Cindy Neunert, Prof. David Kuter, Dr María Eva Mingot Castellano

Leading experts discuss the impact of ITP on patients and review current and emerging treatment strategies.

99 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCLINICAL PERSPECTIVES

Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease

Dr Helena Yu, Dr Antonio Passaro, Dr Aaron Lisberg, Dr Sara Pilotto, Ms Jackie Fenemore, Prof. Egbert Smit

Experts provide insights on tailoring treatment in patients with EGFR-mutant and wildtype NSCLC.

Translations available:
39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT

Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors

Dr Lizza Hendriks, Dr Jacob Sands, Prof. Suresh Senan

A multidisciplinary team discusses the role of immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC).

Translations available:
55 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT

Precision targeting of MET in NSCLC: A multidisciplinary approach

Dr Xiuning Le, Dr Christine Argento, Dr Sandra Cuellar, Ms Stephanie McDonald, Prof. Albrecht Stenzinger

A multidisciplinary team of specialists discuss the use of targeted therapies for NSCLC with MET alterations.

15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchFOCUS

Targets in early NSCLC: A focus on EGFR-mutant treatment options

Dr Jennifer Carlisle

Watch an expert in lung cancer discuss the treatment options for patients with early-stage EGFR-mutant NSCLC

55 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS

Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024

Prof. María-Victoria Mateos, Dr Rakesh Popat, Prof. Evangelos Terpos

Three experts discuss data presented at COMy and EHA 2024 on BCMA-targeting agents in multiple myeloma.

Translations available:
15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchFOCUS

Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors

Prof. Barbara Burtness

Watch Prof. Barbara Burtness provide an update on the evolving role of ICIs in the management of RM-NPC.

41 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Expanding HER2 horizons: Implications for NSCLC and beyond

Dr Razelle Kurzrock, Dr Lyudmila Bazhenova, Dr Ignacio Wistuba

Two oncologists and a pathologist discuss the implications of HER2 targeting in solid tumours, with a focus on NSCLC.

Translations available:
51 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS

Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?

Dr Vickie McDonald, Prof. Waleed Ghanima, Prof. James B Bussel

Three experts discuss data presented at EHA and ISTH 2024 on the impact and management of ITP.

Translations available:

Society & Congress Partners

touchONCOLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events

View All
18 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchFOCUS

Personalizing care within the MDT for patients with early through to advanced RCC

Prof. Hans Hammers

Watch an expert in RCC discuss multidisciplinary team care for patients with early through advanced disease.

39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma: From optimal sequencing to shared decision-making

Dr Matthew Lunning, Professor Charalambos Andreadis, Dr Tara Graff

Haematology experts discuss the latest on novel therapies and treatment selection and sequencing in R/R FL

Translations available:
15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchFOCUS

Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches

Dr Dana Chase

Watch Dr Dana Chase discuss the role of HER2 as a pan-tumour biomarker and the implications for treatment.

39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION

Knowledge for nurses: ADC updates in breast cancer

Ms Nikolina Dodlek, Prof. Sherko Kümmel

Watch an oncology nurse and a medical oncologist discuss the use of HER2-directed ADCs in breast cancer.

Translations available:
37 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION

Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies

Prof. Enriqueta Felip, Prof. Keith Kerr

An oncologist and a pathologist discuss HER2 testing and treatments for HER2-altered NSCLC.

Translations available:
52 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management

Prof. Dr Vito Sabato, Dr Sigurd Broesby-Olsen, Prof. Prithviraj Bose

Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.

Translations available:
33 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS

Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines

Prof. Heather A Wakelee

Prof. Wakelee discusses the latest evidence on immunotherapy for early-stage, resectable NSCLC.

Translations available:
32 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS

Advanced urothelial carcinoma: Expert guidance to navigate an evolving therapeutic landscape

Prof. Thomas Powles

Prof. Powles considers the latest developments in the treatment of advanced urothelial carcinoma.

Translations available:
38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS

Clinical decision making with immunotherapies in advanced or recurrent endometrial cancer

Prof. David Cibula

Hear expert insights on the role of immunotherapy in treating advanced/recurrent endometrial cancer.

Load More...

All touchIME CME activities are accredited. Learners can claim ACCME, ANCC, ACPE or EBAC credits upon completion of the activities. This content is for healthcare professionals only.

Latest Medical Education - straight to your inbox

Close Popup